REFERENCES
1. 2020 plastic surgery statistics report. Available from: https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic-surgery-statistics-full-report-2020.pdf [Last accessed on 19 Apr 2024].
2. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 2008;115:559-65.
3. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992;18:17-21.
4. Whitcup SM, Hallett M. Botulinum toxin therapy. Springer; 2021.p.1-289.
5. Park MY, Ahn KY. Scientific review of the aesthetic uses of botulinum toxin type A. Arch Craniofac Surg 2021;22p:1-10.
6. Bach K, Simman R. The multispecialty toxin: a literature review of botulinum toxin. Plast Reconstr Surg Glob Open 2022;10:e4228.
7. Coetzee S, Nunez N, Belaunzaran M, Mark J, Stickler MA. Beyond wrinkles: a comprehensive review of the uses of botulinum toxin. J Drugs Dermatol 2023;22:7243e.
8. Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic use of botulinum neurotoxins in dermatology: systematic review. Toxins 2021;13:120.
9. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthetic Dermatol 2014;7:31-9.
10. Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006;81:1023-8.
11. Lewandowski M, Świerczewska Z, Barańska-Rybak W. Off-label use of botulinum toxin in dermatology-current state of the art. Molecules 2022;27:3143.
12. Naik PP. Utilities of botulinum toxins in dermatology and cosmetology. Clin Cosmet Investig Dermatol 2021;14:1319-30.
13. Padda IS, Tadi P. Botulinum toxin. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557387/ [Last accessed on 19 Apr 2024].
14. Shuo L, Ting Y, KeLun W, Rui Z, Rui Z, Hang W. Efficacy and possible mechanisms of botulinum toxin treatment of oily skin. J Cosmet Dermatol 2019;18:451-7.
15. Yi KH, Lee JH, Kim SO, et al. Botulinum neurotoxin injection for treating plunged nose and post-rhinoplasty: anatomical perspectives of depressor septi nasi, nasalis, leveator labii superioris alaeque nasi muscle. Anat Cell Biol 2023;56:409-14.
16. Fatani B. An approach for gummy smile treatment using botulinum toxin a: a narrative review of the literature. Cureus 2023;15:e34032.
17. Yi KH, Lee JH, Hu HW, et al. Novel anatomical proposal for botulinum neurotoxin injection targeting depressor anguli oris for treating drooping mouth corner. Anat Cell Biol 2023;56:161-5.
18. Yi KH, Kim SB, Kim HJ. Ultrasonographic observations of the paradoxical mentalis bulging in regard to botulinum neurotoxin injection for mentalis muscle. Skin Res Technol 2023;29:e13517.
19. Yi KH, Lee JH, Lee K, Hu HW, Lee HJ, Kim HJ. Anatomical proposal for botulinum neurotoxin injection targeting the platysma muscle for treating platysmal band and jawline lifting: a review. Toxins 2022;14:868.
20. Yi KH, Lee JH, Hu HW, Kim HJ. Novel anatomical guidelines on botulinum neurotoxin injection for wrinkles in the nose region. Toxins 2022;14:342.
21. Kontis TC, Lacombe VG. Cosmetic injection techniques: a text and video guide to neurotoxins and fillers. Thieme; 2019.p.1-226.
22. Semchyshyn N, Sengelmann RD. Botulinum toxin A treatment of perioral rhytides. Dermatol Surg 2003;29:490-5; discussion 495.
23. Loyo M, Kontis TC. Cosmetic botulinum toxin: has it replaced more invasive facial procedures? Facial Plast Surg Clin North Am 2013;21:285-98.
24. Yi KH, Lee HJ, Hur HW, Seo KK, Kim HJ. Guidelines for botulinum neurotoxin injection for facial contouring. Plast Reconstr Surg 2022;150:562e-71e.
25. Yi KH, Lee HJ, Choi YJ, Lee K, Lee JH, Kim HJ. Anatomical guide for botulinum neurotoxin injection: application to cosmetic shoulder contouring, pain syndromes, and cervical dystonia. Clin Anat 2021;34:822-8.
26. Phan K, Younessi S, Dubin D, Lin MJ, Khorasani H. Emerging off-label esthetic uses of botulinum toxin in dermatology. Dermatol Ther 2022;35:e15205.
27. Yi KH, Park HJ, Kim JH, et al. Intramuscular neural distribution of the gastrocnemius for botulinum neurotoxin injection: application to cosmetic calf shaping. Yonsei Med J 2023;64:511-7.
28. Galderma R&D. Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (READY-4). Available from: https://clinicaltrials.gov/study/NCT04225260 [Last accessed on 19 Apr 2024].
29. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 2010;4:325-32.
30. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006;13 Suppl 4:10-9.
31. Sharma SK, Singh BR. Immunological properties of Hn-33 purified from type A clostridium botulinum. J Nat Toxins 2000;9:357-62.
32. Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. Neurotox Res 2016;29:105-17.
33. Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ. Overview of DaxibotulinumtoxinA for injection: a novel formulation of botulinum toxin type a. Drugs 2021;81:2091-101.
34. Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs RD 2010;10:67-73.
35. Field M, Splevins A, Picaut P, et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin content and potential implications for duration of response in patients. Toxins 2018;10:535.
36. Kwiat DM, Bersani TA, Bersani A. Increased patient comfort utilizing botulinum toxin type a reconstituted with preserved versus nonpreserved saline. Ophthalmic Plast Reconstr Surg 2004;20:186-9.
37. Alam M, Dover JS, Klein AW, Arndt KA. Botulinum a exotoxin for hyperfunctional facial lines: where not to inject. Arch Dermatol 2002;138:1180-5.
38. Gassner HG, Sherris DA. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. Mayo Clin Proc 2000;75:701-4.
39. Yen MT, Wall VK. Bupivacaine-induced myotoxicity and its effect on botulinum toxin paresis. Ann Plast Surg 2008;60:6-9.
40. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990;12:392-9.
42. Yaraskavitch M, Leonard T, Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech 2008;41:897-902.
43. Eleopra R, Tugnoli V, Caniatti L, De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996;46:1158-60.
44. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004;140:1351-4.
45. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013;28:1775-83.
46. Jensen JD, Freeman SR, Cohen JL. Botulinum toxins. In: Draelos ZD, editor. Cosmetic Dermatology. Wiley; 2015. pp. 364-74.
47. DailyMed. BOTOX COSMETIC - onabotulinumtoxina injection, powder, lyophilized, for solution. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab [Last accessed on 19 Apr 2024].
48. Kassir M, Gupta M, Galadari H, et al. Complications of botulinum toxin and fillers: a narrative review. J Cosmet Dermatol 2020;19:570-3.
49. Witmanowski H, Błochowiak K. The whole truth about botulinum toxin - a review. Postepy Dermatol Alergol 2020;37:853-61.
50. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part II: Wrinkles on the middle and lower face, neck and chest. J Eur Acad Dermatol Venereol 2010;24:1285-95.
51. Rzany B, Zielke H. Safety of botulinum toxin in aesthetic medicine. In: de Maio M, Rzany B, editors. Botulinum Toxin in Aesthetic Medicine. Berlin: Springer Berlin Heidelberg; 2007. pp. 119-25.
52. Yılmaz D, Düzgün F, Durmaz H, Çinar HG, Dikmen Y, Kara H. The effect of duration of pressure on bruising and pain in the subcutaneous heparin injection site. Jpn J Nurs Sci 2020;17:e12325.
53. Ho B, Jagdeo J, Waldorf HA. Is there a role for arnica and bromelain in prevention of post-procedure ecchymosis or edema? a systematic review of the literature. Dermatol Surg 2016;42:445-63.
54. Carruthers A, Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998;24:1189-94.
55. Klein AW. Complications and adverse reactions with the use of botulinum toxin. Dis Mon 2002;48:336-56.
57. Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg 2001;20:71-84.
58. Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 2001;108:208-14; discussion 215.
59. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 2004;22:66-75.
60. Bae JH, Choi DY, Lee JG, Seo KK, Tansatit T, Kim HJ. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy. Dermatol Surg 2014;40:1334-9.
61. Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg 2001;20:109-20.
